ERAS Stock — Erasca, Inc.

Up next

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 11, 2026

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 14.9 · calm Equity put/call 0.52

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +42%

above

Price vs 50-day avg −3%

below

RSI (14) 42

neutral

MACD trend Negative

52-week position 74%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return −12%

trailing

6-month return +25%

trailing

YTD return +359%

this year

Relative strength +14%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $18 › 200d $12 — 50d above 200d

Institutional flow Accumulating

+13% holders QoQ · +61 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

8.56% of float · ▼ -2.6% MoM · 7.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

256 holders — near 3-yr high, broad support

Squeeze score 78

high risk · 0–100

Fundamentals

Strong

EPS growth +36%

Y/Y

Free cash flow $-95.6M

Balance sheet $73.8M

net cash

Quant / Vol

risk profile

Very High

Volatility 104%

annualized · 1-yr

Max drawdown −59%

past year

ATR 6.3%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

1 · 5 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+42% Bullish

Price vs 50-day avg

−3% Neutral

RSI (14)

42 Neutral

MACD trend

Negative Bearish

52-week position

74% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $18 › 200d $12 — 50d above 200d

Institutional flow Accumulating

+13% holders QoQ · +61 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

8.56% of float · ▼ -2.6% MoM · 7.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

256 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $1 Now $17 · 74% Range high $22

vs 200-day avg +42% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
cash, cash equivalents and marketable securities	$341.8M	year ended December 31, 2025	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ERAS Erasca, Inc. this stock	$6.23B	+359.1%	—	—	8.6%
ONC BeOne Medicines Ltd.	$557.05B	+21.5%	+22179.2%	856.5	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$136.93B	+19.2%	+46.2%	31.5	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$86.39B	+7.1%	+20.8%	20.8	3.3%
MRNA Moderna, Inc.	$69.62B	+352.1%	+4.3%	—	12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

256

% held: 82.6%
Net QoQ: +12.9M sh
Top holder: Frazier Life Sciences Man…

Held Float

View

Held by Funds

Fund positions

229

View

Short & Settlement

Short Interest Falling

Shares short

30.0M

Days to cover: 7.3d
Change: -812.8K sh

View

Short Volume

Short vol %

47%

As of: Aug 20, 2026

Short Total

View

Fails to Deliver

FTD shares

902

Value: $16.0K
As of: Jul 30, 2026

View

Off-Exchange

Off-exchange %

39.9%

Week of: Jul 13, 2026

Off-exch Lit

View

Financials

Net income (FY)

$-124.5M

EPS diluted: $-0.44

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 11, 2026
This year: 18

View

Proposed Sales

Value

$1.3M

Shares: 80.0K
Filed: Apr 1, 2026

View

Exempt Offerings

Offering

$374.5M

Filed: Apr 30, 2020

View

Earnings & Events

Earnings Calls

Last call

May 8, 2024

View

	5D	20D	120D	MTD	YTD
ERAS	-4.4%	-11.7%	+25.0%	-5.9%	+359.1%
SPY	-2.0%	+3.3%	+11.2%	+2.1%	+11.8%
vs SPY	-2.4%	-15.0%	+13.9%	-8.0%	+347.3%

ERAS · Erasca, Inc.

Price & Indicators

Up next

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance